Lexeo Therapeutics Appoints Tim Van Hauwermeiren to its Board of Directors

July 8, 2024

https://www.globenewswire.com/news-release/2024/07/08/2909483/0/en/Lexeo-Therapeutics-Appoints-Tim-Van-Hauwermeiren-to-its-Board-of-Directors.html

NEW YORK, July 08, 2024 (GLOBE NEWSWIRE) — Lexeo Therapeutics, Inc. (Nasdaq:LXEO), a clinical stage genetic medicine company, today announced the appointment of Tim Van Hauwermeiren, co-founder and Chief Executive Officer of argenx SE, as an independent, non-executive director to its Board of Directors. Mr. Van Hauwermeiren is a seasoned biotech executive with over two decades of experience in both general management and business development across the life sciences and consumer goods industries.  

Read more at globenewswire.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.